GRAPIPRANT

It’s only fair to share… GRAPIPRANT Molecular FormulaC26H29N5O3S Average mass491.605 Da CAS 415903-37-6 UNII-J9F5ZPH7NB, CJ 023423, CJ-023423, Phase II, Arrys Therapeutics, CANCER, PAIN, AskAt Phase II,  N-{2-[4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl}-N’-[(4-methylphenyl)sulfonyl]urea RQ-00000007, MR10A7 9763 AAT-007 Benzenesulfonamide, N-[[[2-[4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]amino]carbonyl]-4-methyl- CJ-023,423 N-[[[2-[4-(2-Ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]amino]carbonyl]-4-methylbenzenesulfonamide 1-[2-[4-(2-Ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea 2-Ethyl-4,6-dimethyl-1-[4-[2-[[[[(4-methylphenyl)sulfonyl]amino]carbonyl]amino]ethyl]phenyl]-1H-imidazo[4,5-c]pyridine AAT 007 CJ 023423 Grapiprant MR 10A7 RQ 00000007 RQ 7 Synonyms and Mappings 415903-37-6 GRAPIPRANT [GREEN BOOK] CJ-023 GRAPIPRANT [INN] GRAPIPRANT [WHO-DD] MR-10A7 …

Brilliant blue G , ブリリアントブルーG ,

It’s only fair to share…   Brilliant blue G FDA 2019, 12/20/2019, TISSUEBLUE, New Drug Application (NDA): 209569 Company: DUTCH OPHTHALMIC, PRIORITY; Orphan OPQ recommends APPROVAL of NDA 209569 for commercialization of TissueBlue (Brilliant Blue G Ophthalmic Solution), 0.025% Neuroprotectant sodium;3-[[4-[[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]-2-methylcyclohexa-2,5-dien-1-ylidene]methyl]-N-ethyl-3-methylanilino]methyl]benzenesulfonate Formula C47H48N3O7S2. Na CAS 6104-58-1 Mol weight 854.0197 ブリリアントブルーG, C.I. Acid Blue 90 UNII-M1ZRX790SI M1ZRX790SI 6104-58-1 Brilliant Blue G Derma …

Fluorodopa F 18, フルオロドパ (18F), флуородопа (18F) , فلورودوبا (18F) , 氟[18F]多巴 ,

It’s only fair to share… Fluorodopa F 18 2019/10/10, fda 2019, Formula C9H10FNO4 Cas 92812-82-3 Mol weight 215.1784 Diagnostic aid (brain imaging), Radioactive agent, for use in positron emission tomography (PET) CAS 92812-82-3 フルオロドパ (18F) L-6-(18F)Fluoro-DOPA L-Tyrosine, 2-fluoro-18F-5-hydroxy- [ACD/Index Name] флуородопа (18F) [Russian] [INN] فلورودوبا (18F) [Arabic] [INN] 氟[18F]多巴 [Chinese] [INN] ((18)F)FDOPA 2-(fluoro-(18)F)-5-hydroxy-L-tyrosine 2-(Fluoro-18F)-5-hydroxy-L-tyrosine 2-(Fluoro-18F)-L-DOPA 2C598205QX 6-((18)F)fluoro-L-DOPA 6-(18F)Fluoro-L-DOPA 6692 (18F)FDOPA 2-((18)F)fluoro-5-hydroxy-L-tyrosine Fluorodopa, also …

Enfortumab vedotin

It’s only fair to share… Enfortumab vedotin Formula C6642H10284N1742O2063S46 Cas 1346452-25-2 Mol weight 149022.148 AGS-22M6E, enfortumab vedotin-ejfv Fda approved 2019/12/18, Padcev Antineoplastic, Nectin-4 antibody, Tubulin polymerization inhibitor, Urothelial cancer エンホルツマブベドチン (遺伝子組換え); protein Based Therapies, Monoclonal antibody, mAb,  UNII DLE8519RWM Immunoglobulin G1, anti-(human nectin-4) (human monoclonal AGS-22C3 γ1-chain), disulfide with human monoclonal AGS-22C3 κ-chain, dimer, tetrakis(thioether) with N-[[[4-[[N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide Other Names AGS 22CE AGS …

RESMETIROM

It’s only fair to share… RESMETIROM C17H12Cl2N6O4 435.2 g/mol MGL-3196 CAS 920509-32-6, Resmetirom, VIA-3196, UNII-RE0V0T1ES0 Phase III, Non-alcoholic fatty liver disease (NAFLD) 2-[3,5-dichloro-4-[(6-oxo-5-propan-2-yl-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 2-(3,5-DICHLORO-4-((5-ISOPROPYL-6-OXO-1,6-DIHYDROPYRIDAZIN-3-YL)OXY)PHENYL)-3,5-DIOXO-2,3,4,5-TETRAHYDRO-(1,2,4)TRIAZINE-6-CARBONITRILE 1,2,4-TRIAZINE-6-CARBONITRILE, 2-(3,5-DICHLORO-4-((1,6-DIHYDRO-5-(1-METHYLETHYL)-6-OXO-3-PYRIDAZINYL)OXY)PHENYL)-2,3,4,5-TETRAHYDRO-3,5-DIOXO- Madrigal Pharmaceuticals , following the merger between Synta and Madrigal Pharmaceuticals (pre-merger) (following the acquisition of  VIA Pharmaceuticals ‘ assets (originally under license from  Roche )), is developing resmetirom (MGL-3196, VIA-3196), the lead from oral …

Avapritinib, アバプリチニブ , авапритиниб , أفابريتينيب ,

It’s only fair to share… Avapritinib BLU-285, BLU285 Antineoplastic, Tyrosine kinase inhibitor アバプリチニブ авапритиниб [Russian] [INN] أفابريتينيب [Arabic] [INN] (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine (1S)-1-(4-Fluorophenyl)-1-(2-{4-[6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]-1-piperazinyl}-5-pyrimidinyl)ethanamine 10613 1703793-34-3 [RN] 513P80B4YJ 5-Pyrimidinemethanamine, α-(4-fluorophenyl)-α-methyl-2-[4-[6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]-1-piperazinyl]-, (αS)- (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethan-1-amine (αS)-(4-fluorophenyl)-α-methyl-2-[4-[6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]-1-piperazinyl]-5-pyrimidinemethanamine Formula C26H27FN10 CAS 1703793-34-3 Mol weight 498.558 No. Drug Name Active Ingredient Approval Date FDA-approved use on approval date* 1. Ayvakit avapritinib 1/9/2020 To treat adults with unresectable or metastatic …

TERIPARATIDE, テリパラチド , терипаратид , تيريباراتيد , 特立帕肽 ,

It’s only fair to share… TERIPARATIDE テリパラチド; терипаратид [Russian] [INN] تيريباراتيد [Arabic] [INN] 特立帕肽 [Chinese] [INN] PTH 1-34 LY 333334 / LY-333334 / LY333334 / ZT-034 Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His Asn Phe-OH   Type Peptide Formula C181H291N55O51S2 CAS 52232-67-4 99294-94-7 …

Coblopasvir

It’s only fair to share… Coblopasvir CAS: 1312608-46-0 Chemical Formula: C41H50N8O8 Molecular Weight: 782.89 UNII-67XWL3R65W methyl {(2S)-1-[(2S)-2-(4-{4-[7-(2-[(2S)-1-{(2S)-2- [(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-4-yl)-2H-1,3-benzodioxol-4-yl]phenyl}-1Himidazol-2-yl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate Carbamic acid, N-((1S)-1-(((2S)-2-(5-(4-(7-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methyl-1-oxobutyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-1,3-benzodioxol-4-yl)phenyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)-, methyl ester hepatitis C virus infection KW-136 Coblopasvir is an antiviral drug candidate. Coblopasvir dihydrochloride CAS 1966138-53-3 C41 H50 N8 O8 . 2 Cl H  Molecular Weight 855.806 PHASE 3 Beijing Kawin Technology Share-Holding Hepatitis …

ADAFOSBUVIR, адафосбувир , أدافوسبوفير ,

It’s only fair to share… ADAFOSBUVIR AL335; ALS-335; JNJ-64146212 , D11364 адафосбувир [Russian] [INN] أدافوسبوفير [Arabic] [INN] Propan-2-yl N-((P5’S)-4′-fluoro-2′-C-methyl-p-o-phenyl- 5′-uridylyl)-L-alaninate propan-2-yl (2S)-2-{[(S)-{[(2S,3S,4R,5R)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-2-fluoro-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate Isopropyl (2S)-2-{[(S)-{[(2S,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl)-2-fluoro-3,4-dihydroxy-4-methyltetrahydro-2-furanyl]methoxy}(phenoxy)phosphoryl]amino}propanoate (non-preferred name Propan-2-yl N-((P5’S)-4′-fluoro-2′-C-methyl-p-o-phenyl- 5′-uridylyl)-L-alaninate 545.5 g/mol, C22H29FN3O10P CAS Registry Number 1613589-09-5 Adafosbuvir is under investigation in clinical trial NCT02894905 (A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335). Originator Alios BioPharma Developer Alios BioPharma; …

Cefiderocol, セフィデロコル , цефидерокол , سيفيديروكول , 头孢德罗 ,

It’s only fair to share…   Cefiderocol セフィデロコル; Formula C30H34ClN7O10S2 CAS 1225208-94-5 Mol weight 752.2149 Antibacterial, Cell wall biosynthesis inhibitor, enicillin binding protein, Siderophore cephalosporin Fetroja (TN) FDA, Cefiderocol, APPROVED, 2019/11/14 (6R,7R)-7-{[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-{[(2-carboxy-2-propanyl)oxy]imino}acetyl]amino}-3-[(1-{2-[(2-chloro-3,4-dihydroxybenzoyl)amino]ethyl}-1-pyrrolidiniumyl)methyl]-8-oxo-5-thia-1-azabicycl o[4.2.0]oct-2-ene-2-carboxylate S-649266,  GSK 2696266D Cefiderocol, sold under the brand name Fetroja, is an antibiotic used to treat complicated urinary tract infections when no other options are available.[2] It is indicated for the treatment of multi-drug-resistant Gram-negative bacteria including Pseudomonas …